BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directorate of the Company.23-07-2021
23-07-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr.22-07-2021
BIOCON LTD. - 532523 - Financial Results For The Quarter Ended June 30, 2021.
Financial Results for the quarter ended June 30, 2021.22-07-2021
BIOCON LTD. - 532523 - Financial Results For The Quarter Ended June 30, 2021
Financial Results for the quarter ended June 30, 202122-07-2021
Biocon Ltd - 532523 - Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
In continuation to our letter dated November 7, 2020, wherein it was intimated that Biocon Limited (the 'Company'), Biocon Biologics Limited ('BBL'), and Goldman Sachs India AIF Scheme - 1 and 2, schemes setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited (the 'Investor') had executed a Securities Subscription Agreement dated November 7, 2020 ('SSA') and in continuation to our letter dated January 7, 2021, wherein it was intimated that the Company, BBL, the Investor, Tata Capital Growth Fund II, Activ Pine LLP and Beta Oryx Limited (collectively with the Investor, the Existing Investors) had executed a Shareholders' Agreement dated January 7, 2021 ('SHA') (SSA together with the SHA, hereinafter called as 'Transaction Documents').15-07-2021
BIOCON LTD. - 532523 - Shareholding for the Period Ended June 30, 2021
Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here12-07-2021
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2021.12-07-2021
Biocon Ltd - 532523 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 032320 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer09-07-2021
BIOCON LTD. - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Trading Window Closure
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, July 22, 2021, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter ended June 30, 2021, amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from July 1, 2021 to July 24, 2021 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations. The above mentioned information will also be available on website of the Company at www.biocon.com.06-07-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement02-07-2021